Home > Boards > US Listed > Biotechs >

Regen Preferred (RGBPP)

RGBPP RSS Feed
Add RGBPP Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 3/4/2021 8:53:10 AM - Followers: 51 - Board type: Free - Posts Today: 0


https://www.regenbiopharmainc.com/


Fast Forwarding Checkpoint Medicine
Striving to improve the quality of life by introducing the latest in medical technology for treating cancer and autoimmunity
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space.
The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials.
Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. 
The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax),
modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS),
and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

2018-NEWS;
February 21, 2018 | SOURCE: PRNewswire | Regen BioPharma, Inc. Program to Determine the 3-D Crystal Structure of NR2F6 Progresses to Next Step
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has moved into the second stage of its previously-announced program to determine the
three-dimensional structure of NR2F6 - with and without its proprietary small molecule drugs bound to it.
The object of this structure-determination program is to shed light on how the small molecules bind to and modulate NR2F6 activity.
DOWNLOAD>>>

January 17, 2018 | SOURCE: PRNewswire | Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element
whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company's contract research organization.
DOWNLOAD>>>
 

2017
November 27, 2017 | SOURCE: PRNewswire | Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has initiated in vivo and ex vivo assessments to determine the effects of some of the
Company's NR2F6 small molecule agonists in live rats and in tissues derived from humans and rats.
Key attributes that are being measured include pH, plasma and liver microsomal stability, along with pharmacokinetics.
DOWNLOAD>>>

November 16, 2017 | SOURCE: PRNewswire | Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6
18 months ago, Regen BioPharma Inc. (OTCQB: RGBP)(OTCQB: RGBPP) commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.
Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient's own immune system.
Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders.
DOWNLOAD>>>

November 8, 2017 | SOURCE: PRNewswire | Regen BioPharma's Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) recently began a program to determine the three-dimensional structure of the NR2F6 nuclear receptor.
In addition, the Company recently reported that its NR2F6 medicinal chemistry program identified key structural elements in small molecules that make them active and specific towards the NR2F6 target.
DOWNLOAD>>>

October 30, 2017 | SOURCE: PRNewswire | Regen BioPharma, Inc. Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (BAB)
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) announced that former Eli Lilly executive Jean-Pierre Millon will serve as chairman of its newly formed business advisory board (BAB).
The Company also announced that two esteemed life science and healthcare executives have agreed to serve as members of the BAB.
The advisory board will assist Regen's management team in evaluating partnership and licensing opportunities related to the company's intellectual property including its NR2F6 program.

https://www.regenbiopharmainc.com/products.html
https://www.regenbiopharmainc.com/company-news.html

 

DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.

 








 
RGBPP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RGBPP News: Current Report Filing (8-k) 01/22/2020 04:05:41 PM
RGBPP News: Current Report Filing (8-k) 01/07/2020 04:35:27 PM
RGBPP News: Current Report Filing (8-k) 12/18/2019 10:49:56 AM
RGBPP News: Current Report Filing (8-k) 11/18/2019 05:17:21 PM
RGBPP News: Quarterly Report (10-q) 10/24/2019 02:42:35 PM
PostSubject
#1765   try this link ,,,https://docoh.com/company/1589150/RGBP ronrooster 03/04/21 08:53:10 AM
#1764   Good Morning, just found this NEW PATENT APPLICATION ....http://appft1.uspto.gov ronrooster 03/04/21 08:32:41 AM
#1763   ME TOO !$!$!$!$! AND WE WILL BE RICH IN TAKURI 03/04/21 03:30:38 AM
#1762   I have both the common and pr joe botts 03/03/21 05:15:46 PM
#1761   IB restricted me to buy yesterday I...M...T...L....(?) I had TAKURI 03/02/21 06:20:25 AM
#1760   INTERACTIVE BROKERS RESTRICTED ME TO BUY MORE SHARES tortiello 03/02/21 03:44:10 AM
#1759   Also, does everyone know that OTC companies must metslinger61 02/25/21 05:47:46 PM
#1758   Stop sign! When will RGBPP file to be current?? metslinger61 02/25/21 05:33:12 PM
#1757   I AGREE WITH YOU !$!$!$!$!$!$!$! TAKURI 02/25/21 12:46:41 PM
#1756   Falzan Lolo12 02/25/21 10:31:35 AM
#1755   oh, I CAN NOT WAIT! SidVicious 02/25/21 10:25:16 AM
#1754   News this week or Monday Lolo12 02/24/21 03:01:56 PM
#1753   Awesome chart here. Regen is holding strong! Market Timingpennies 02/18/21 01:37:16 PM
#1752   I_WILL_NEVER_SELL_REGEN Here's why. Timingpennies 02/03/21 09:32:38 AM
#1751   https://otcbb.swingtradebot.com/equities/RGBPP N.Y. , NASDAQ mick 01/31/21 11:04:33 PM
#1750   found out I still have some preferred of giabull 01/29/21 11:21:47 AM
#1749   noted. I found out the hard way. archilles 01/08/21 03:28:42 PM
#1748   Because there is no company! lab40 01/08/21 02:56:13 PM
#1747   https://pennystocks.news/otc/?symbol=RGBPP mick 01/03/21 01:50:42 PM
#1746   Funny cause they reply pretty quickly gotinearly 12/30/20 11:16:59 AM
#1745   I have been trying to do a dd archilles 12/30/20 11:06:17 AM
#1744   Regen Biopharma Inc (RGBPP) mick 12/07/20 03:18:12 PM
#1743   EYE EYE, AGREE PAL~ EASY ADDS DOWN HERE 1TIMEPLEASEGOUPPPPP 12/05/20 10:19:35 AM
#1742   Yes under valued if x10 lower market cap LETSWIN2020 12/04/20 03:04:08 PM
#1741   This should run hard with RGBP. This currently BinDaddy 12/02/20 08:51:56 PM
#1740   watching closely tomorrow aristotelisonassis 12/02/20 07:24:01 PM
#1739   Regen Biopharma Inc (RGBPP) mick 10/25/20 04:45:14 PM
#1738   RGBP Getting Big volume. $RGBPP definitely a lean 9754LB851 10/02/20 12:07:43 PM
#1737   Regen Biopharma Inc (RGBPP) mick 09/24/20 08:43:21 PM
#1736   Regen Biopharma Inc (RGBPP) mick 09/05/20 02:44:56 PM
#1735   Regen Biopharma Inc (RGBPP) mick 08/16/20 01:51:15 PM
#1734   The problem is as you stated,a bunch of ronrooster 08/15/20 09:59:17 AM
#1733   Hah I know, they keep deleting my posts. SanDiegoAlan 08/15/20 03:27:56 AM
#1732   Looking better this morning, some nice buys. ronrooster 08/14/20 11:35:57 AM
#1731   Looks like LG CAPITAL is unloading? ronrooster 08/13/20 10:10:09 AM
#1730   with all the action with rgbp the last ronrooster 08/12/20 02:14:50 PM
#1729   rgbp worth lies with the Zander patents. not ronrooster 08/12/20 02:11:16 PM
#1728   the boys on rgbp board are deleting any ronrooster 08/12/20 02:10:07 PM
#1727   rgbp mainly sells today , 100 m, no ronrooster 08/12/20 02:09:06 PM
#1726   rgbp classic pump and dump almost over.mainly sells today ronrooster 08/12/20 02:08:25 PM
#1725   $RGBPP NEEDS SOME NEWS mick 07/29/20 09:32:25 AM
#1724   crazy for sure gotinearly 07/29/20 08:35:11 AM
#1723   mick, what do you think gotinearly 07/29/20 08:34:33 AM
#1722   would love to know if anybody has heard gotinearly 07/29/20 08:33:57 AM
#1721   interesting this thing seems to still have a gotinearly 07/29/20 08:33:19 AM
#1720   Preying on the despondent owners of pets suffering SanDiegoAlan 07/28/20 05:06:11 AM
#1719   $RGBPP Regen Biopharma Inc (RGBPP) mick 07/25/20 01:53:18 PM
#1718   Sister ZANDER just granted PATENT re dogs/cancer. ronrooster 07/22/20 02:47:33 PM
#1717   Regen Biopharma Inc (RGBPP) mick 07/16/20 11:36:54 PM
#1716   Regen Biopharma Inc (RGBPP) mick 06/29/20 11:38:37 PM
PostSubject
Consent Preferences